Evaluating Neurodegenerative Biomarkers in Hospitalized Patients With COVID-19, Alzheimer Disease
January 13th 2022Jennifer Frontera, MD, professor of neurology, NYU Langone Grossman School of Medicine, discussed findings from a recently published study investigating neurological complications in hospitalized patients with COVID-19.
NeuroVoices: Orrin Devinsky, MD, on Unanswered Questions With SUDEP, Heart Rate Variability
November 24th 2021The director of the Comprehensive Epilepsy Center at NYU Langone discussed the large-scale impact heart rate variability has on preventing SUDEP and the unanswered questions that remain.
Role Heart Rate Variability Plays in SUDEP Research, Prevention: Orrin Devinsky, MD
November 23rd 2021The director of the Comprehensive Epilepsy Center at NYU Langone discussed the necessary steps in validating and utilizing heart rate variability as a biomarker for SUDEP. [WATCH TIME: 3 minutes]
Heart Rate Variability’s Role in Potential SUDEP-Predicting Modalities: Orrin Devinsky, MD
November 19th 2021The director of the Comprehensive Epilepsy Center at NYU Langone provided insight on whether a newly discovered biomarker can play a role in the creation of modalities to detect SUDEP risk. [WATCH TIME: 3 minutes]
NeuroVoices: Ilya Kister, MD, on Understanding Long-Term Responses to Vaccines in MS
October 27th 2021The professor of neurology at the NYU Grossman School of Medicine provided his thoughts on the VIOLA study and the importance of monitoring cell response of post-vaccinated patients with MS on DMTs.
Debunking Myths About Wearing Off Effect of DMTs for MS: Ilya Kister, MD
October 22nd 2021The professor of neurology at the NYU Grossman School of Medicine discussed his findings presented at ECTRIMS 2021, which did not support the hypothesis of a wearing off effect with ocrelizumab (Ocrevus; Genentech). [WATCH TIME: 4 minutes]
Natalizumab Demonstrates Some Impact on Drug-Resistant Epilepsy
September 27th 2021Despite not achieving statistical significance, there was greater relative reduction in seizure frequency over placebo in those with a structural etiology for focal epilepsy than those without, laying the foundation for future research.
NYU Langone’s Comprehensive Epilepsy Center Elevates Care Standards, Drug Development
August 5th 2021Led by a team of top talents, NYU Langone’s Comprehensive Epilepsy Center’s contributions to drug development and improving the quality of life for patients stand among the field's most important.